JP2025506374A5 - - Google Patents

Info

Publication number
JP2025506374A5
JP2025506374A5 JP2024545861A JP2024545861A JP2025506374A5 JP 2025506374 A5 JP2025506374 A5 JP 2025506374A5 JP 2024545861 A JP2024545861 A JP 2024545861A JP 2024545861 A JP2024545861 A JP 2024545861A JP 2025506374 A5 JP2025506374 A5 JP 2025506374A5
Authority
JP
Japan
Prior art keywords
composition
amount
crystalline form
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024545861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506374A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/061651 external-priority patent/WO2023150500A1/en
Publication of JP2025506374A publication Critical patent/JP2025506374A/ja
Publication of JP2025506374A5 publication Critical patent/JP2025506374A5/ja
Pending legal-status Critical Current

Links

JP2024545861A 2022-02-01 2023-01-31 インターロイキン-23受容体のペプチド阻害剤及びその医薬組成物 Pending JP2025506374A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263305631P 2022-02-01 2022-02-01
US63/305,631 2022-02-01
PCT/US2023/061651 WO2023150500A1 (en) 2022-02-01 2023-01-31 Peptide inhibitors of interleukin-23 receptor and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
JP2025506374A JP2025506374A (ja) 2025-03-11
JP2025506374A5 true JP2025506374A5 (cg-RX-API-DMAC7.html) 2026-02-26

Family

ID=85556753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024545861A Pending JP2025506374A (ja) 2022-02-01 2023-01-31 インターロイキン-23受容体のペプチド阻害剤及びその医薬組成物

Country Status (13)

Country Link
EP (1) EP4472999A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025506374A (cg-RX-API-DMAC7.html)
KR (1) KR20240137102A (cg-RX-API-DMAC7.html)
CN (1) CN118829647A (cg-RX-API-DMAC7.html)
AU (1) AU2023215245A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250172A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002263A1 (cg-RX-API-DMAC7.html)
IL (1) IL314629A (cg-RX-API-DMAC7.html)
MX (1) MX2024009477A (cg-RX-API-DMAC7.html)
PE (1) PE20241895A1 (cg-RX-API-DMAC7.html)
TW (1) TW202342496A (cg-RX-API-DMAC7.html)
UY (1) UY40135A (cg-RX-API-DMAC7.html)
WO (1) WO2023150500A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250139359A (ko) 2023-01-31 2025-09-23 얀센 파마슈티카 엔브이 인터류킨-23 수용체의 결정질 펩티드 억제제의 제조 방법
EP4780453A1 (en) * 2023-09-21 2026-07-29 Janssen Pharmaceutica NV Interleukin-23 receptor antagonist for use in the treatment of ulcerative colitis
WO2025151385A1 (en) * 2024-01-08 2025-07-17 Janssen Pharmaceutica Nv Peptide inhibitors of interleukin-23 receptor and uses thereof
WO2025163534A1 (en) * 2024-01-31 2025-08-07 Janssen Pharmaceutica Nv Crystal form of a peptide inhibitor of interleukin-23 receptor
WO2025243217A1 (en) * 2024-05-22 2025-11-27 Janssen Pharmaceutica Nv Crystal forms of peptide molecules
WO2026106852A1 (en) * 2024-11-15 2026-05-21 Janssen Pharmaceutica Nv Methods of using interleukin-23 receptor antagonists
WO2026114760A1 (en) * 2024-11-29 2026-06-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie

Similar Documents

Publication Publication Date Title
CA2846510C (en) Choline salt of an anti - inflammatory substituted cyclobutenedione compound
CA2592605C (en) Method for stabilizing anti-dementia drug
JP2009537538A5 (cg-RX-API-DMAC7.html)
KR20160101720A (ko) Azd9291을 포함하는 제약 조성물
JP2020523335A5 (cg-RX-API-DMAC7.html)
KR20180066039A (ko) 아파티닙을 포함하는 약학적 조성물
AU2016259762A1 (en) Vortioxetine pyroglutamate
KR101920996B1 (ko) HMG-CoA 환원효소 저해제 및 칼슘채널 차단제를 포함하는 복합제제
US20040157925A1 (en) Stable pharmaceutical composition of pravastatin
KR20140140353A (ko) 안정성 및 약물상호작용이 개선된 경구용 복합 정제 조성물
JP2018145095A (ja) エルロチニブ塩酸塩含有医薬組成物
WO2010120963A1 (en) Tablet formulation for p38 inhibitor and method
WO2018091609A1 (en) Formulation comprising 4-methylpyrazole
WO2015069203A1 (en) Capsule comprising rupatadine fumarate and montelukast sodium
JP2024525954A5 (cg-RX-API-DMAC7.html)
KR101524264B1 (ko) 발사르탄 함유 경구용 약학 조성물
US20150190388A1 (en) Pharmaceutical composition of moxifloxacin hydrochloride and preparation method
JP7423297B2 (ja) 口腔内崩壊錠およびその製造方法
US20160015708A1 (en) Stable dosage forms of imatinib mesylate
RU2022102775A (ru) Фармацевтический препарат
EP3731931A2 (en) Modified release formulations of fesoterodine
AU2017251803B2 (en) Choline salt of an anti-inflammatory substituted cyclobutenedione compound
TR2023002079A2 (tr) Empagli̇flozi̇n i̇çeren bi̇r fi̇lm kapli tablet
EP4420658A1 (en) A film coated tablet comprising empagliflozin
RU2017123772A (ru) Фармацевтическая композиция на основе N-бензил-N-метил-1-фенилпирроло [1,2-a] пиразин-3-карбоксамида